Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 15/20 | 0.48 |
| ▸ | JAK3 | P52333 | 8/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | TYK2 | P29597 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13081497 | 0.92 | MAPK8 (0.52) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL8040865 | 0.90 | MAPK8 (0.54) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL13081581 | 0.88 | MAPK8 (0.57) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL13081068 | 0.88 | MAPK8 (0.52) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL8040575 | 0.87 | MAPK8 (0.54) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL13081061 | 0.87 | MAPK8 (0.56) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL13081201 | 0.87 | MAPK8 (0.56) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL13081016 | 0.86 | MAPK8 (0.57) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL13081204 | 0.86 | MAPK8 (0.49) | MAPK8MAPK10MAPK9JAK2JAK3 | |
| SCHEMBL8051682 | 0.86 | MAPK8 (0.56) | MAPK8MAPK10MAPK9JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | MAPK8 33/4885MAPK10 56/4885MAPK9 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.